Evidence map›Paper›PMID 36804133›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2023

Mortality among solid organ transplant recipients with a pretransplant cancer diagnosis.

Allyson Hart, Ruth M Pfeiffer, Bozena M Morawski, Charles F Lynch, Yun Zeng, Karen Pawlish, Deborah Hurley, Kelly J Yu, Eric A Engels

Open access · greenAbstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Kidney disease and transplantation in childhood cancer survivors.Pediatric nephrology (Berlin, Germany) · 2026
    Review
  3. Review
  4. Article
  5. Evaluating cancer risk profiles in lung transplant recipients.Translational lung cancer research · 2025
    Article
  6. Article
  7. Article
  8. Cure models, survival probabilities, and solid organ transplantation for patients with colorectal cancer.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Allyson HartScientific Registry of Transplant Recipients, Minneapolis, Minnesota, USA. Electronic address: Hart1044@umn.edu.
Ruth M PfeifferDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Bozena M MorawskiCancer Data Registry of Idaho, Idaho Hospital Association, Boise, Idaho, USA.
Charles F LynchUniversity of Iowa Department of Epidemiology, Iowa City, Iowa, USA.
Yun ZengUniversity of North Dakota Department of Pathology, North Dakota Statewide Cancer Registry, Grand Forks, North Dakota, USA.
Karen PawlishNew Jersey State Cancer Registry, New Jersey Department of Health, Trenton, New Jersey, USA.
Deborah HurleySouth Carolina Central Cancer Registry Bureau of Chronic Disease & Injury Prevention, Columbia, South Carolina, USA.
Kelly J YuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Eric A EngelsDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
National Cancer Institute · USFamily Medicine Residency of Idaho · USNew Jersey Department of Health · USSouth Carolina Department of Health and Environmental Control · USUniversity of Iowa · USUniversity of Minnesota · USUniversity of North Dakota · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
NATIONAL CANCER PREVENTION AND CONTROL PROGRAMU58DP000824 · DP · TEXAS STATE DEPT OF HEALTH SERVICES · PI DELGADO, EVELYN · 2007 to 2011
$44.3M
MICHIGAN CANCER PREVENTION & CONTROL PROGRAMU58DP003921 · DP · MICHIGAN STATE DEPARTMENT OF HEALTH AND HUMAN SERVICES · PI BROOKOVER, PATRICIA · 2012 to 2014
$30.7M
Category A - Communities Putting Prevention to WorkU58DP000848 · DP · COLORADO STATE DEPT/PUB HLTH & ENVIRONMT · PI JACOBELLIS, JILLIAN · 2007 to 2011
$25.9M
Infections, immunity, and inflammation in cancerZIACP010150 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ENGELS, ERIC A · 2009 to 2025
$24.0M
NATIONAL CANCER PREVENTION & CONTROL PROGRAM - ILLINOISU58DP003883 · DP · ILLINOIS STATE DEPT OF PUBLIC HEALTH · PI MOODY, CONNY · 2012 to 2014
$22.6M
CALIFORNIA'S PARTICIPATION IN THE NATIONAL CANCER PREVENTION AND CONTRO PROGRAMU58DP000807 · DP · PUBLIC HEALTH INSTITUTE · PI SNIPES, KURT P · 2007 to 2011
$22.5M
GEORGIA COMPREHENSIVE CANCER CONTROL PROGRAMU58DP003875 · DP · GEORGIA DIVISION OF PUBLIC HEALTH · PI O'CONNOR, JEAN CATHERINE · 2012 to 2014
$15.9M
CANCER PREVENTION & CONTROL PROGRAM FOR STATE TERRITORIAL & TRIBAL ORGANIZATIONSU58DP003933 · DP · NC STATE DEPT/HLTH & HUMAN SERVICES · PI NELSON, DEBI · 2012 to 2014
$13.9M
CARDIOVASCULAR HEALTH STUDY (CHS) - TASK AREA C, STUDY CLOSEOUT75N92021D00006 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE · 2021 to 2024
$8.4M
NTP INFORMATION SYSTEMS SUPPORT27305C0011 · NIEHS · Z-TECH CORPORATION · 2007 to 2009
$4.3M
PROVIDE RABBITS, RATS, MICE, HAMSTERS, GERBILS, GUINEA PIGS27307C0011 · NIEHS · PI BOLEN, WAYNE · 2007 to 2007
$500k
CLC NIH HHS 75N90021D00009Intramural NIH HHS ZIA CP010150NCCDPHP CDC HHS U58 DP000807NCCDPHP CDC HHS U58 DP000824NCCDPHP CDC HHS U58 DP000848NCCDPHP CDC HHS U58 DP003875NCCDPHP CDC HHS U58 DP003883NCCDPHP CDC HHS U58 DP003921NCCDPHP CDC HHS U58 DP003933NCI NIH HHS HHSN261201000034CNCI NIH HHS HHSN261201000035CNCI NIH HHS HHSN261201000035INCI NIH HHS HHSN261201000036CNCI NIH HHS HHSN261201000037CNCI NIH HHS HHSN261201800002BNCI NIH HHS HHSN261201800002CNCI NIH HHS HHSN261201800004CNCI NIH HHS HHSN261201800006INCI NIH HHS HHSN261201800013CNCI NIH HHS HHSN261201800013INCI NIH HHS HHSN261201800014CNCI NIH HHS HHSN261201800014INCI NIH HHS HHSN261201800016CNCI NIH HHS HHSN261201800016INCI NIH HHS HHSN261201800020CNCI NIH HHS N01 PC035137NCI NIH HHS N01 PC035139NCI NIH HHS N01 PC035143NCI NIH HHS P30 CA086862NHLBI NIH HHS 75N92021D00006NHLBI NIH HHS 75N92021D00009NIEHS NIH HHS 27305C0011NIEHS NIH HHS 27307C0011NIEHS NIH HHS 27398C0011NIEHS NIH HHS 75N96021D00006NIEHS NIH HHS 75N96021D00009NIH HHS 75N98021D00006NLM NIH HHS 75N97021D00006ORFDO NIH HHS 75N99021D00009
6 · The paper itself

Abstract

Little is known about the outcomes among solid organ transplant recipients with a pretransplant cancer diagnosis. We used linked data from the Scientific Registry of Transplant Recipients with 33 US cancer registries. Cox proportional hazards models assessed associations of pretransplant cancer with overall mortality, cancer-specific mortality, and development of a new posttransplant cancer. Among 311 677 recipients, the presence of a single pretransplant cancer was associated with increased overall mortality (adjusted hazard ratio [aHR], 1.19; 95% CI, 1.15-1.23) and cancer-specific mortality (aHR, 1.93; 95% CI, 1.76-2.12); results for 2+ pretransplant cancers were similar. Cancer-specific mortality was not significantly increased for uterine, prostate, or thyroid cancers (aHRs were 0.83, 1.22, and 1.54, respectively) but strongly elevated for lung cancer and myeloma (aHRs were 3.72 and 4.42, respectively). A pretransplant cancer diagnosis was also associated with increased risk of developing posttransplant cancer (aHR, 1.32; 95% CI, 1.23-1.40). Among 306 recipients whose cancer death was confirmed by cancer registry data, 158 deaths (51.6%) were from a de novo posttransplant cancer and 105 (34.3%) from the pretransplant cancer. Pretransplant cancer diagnoses are associated with increased mortality after transplantation, but some deaths are related to posttransplant cancers and other causes. Improved candidate selection and cancer screening and prevention may reduce mortality in this population.

Indexed as

NeoplasmsOrgan TransplantationHumansIncidenceMaleProportional Hazards ModelsRegistriesRisk FactorsTransplant Recipientscancer/malignancy/neoplasiacancer/malignancy/neoplasia: registry/incidencecancer/malignancy/neoplasia: risk factorshealth services and outcomes researchhematology/oncologypatient survivalScientific Registry for Transplant Recipients (SRTR)solid organ transplantation

Identifiers

PMID36804133
PMCPMC9978936
OpenAlexW4315785381

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.